Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder
cancer treatment but responses vary with patients, for reasons that are still not very clear …

Abstract Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) has been implicated in the
etiology of various human malignant tumors; however, its exact role in bladder cancer (BC) …

Purpose Toll-like receptor 4 (TLR4) was found to be aberrantly expressed in bladder cancer,
inducing some genes expression and facilitating tumor progression. Recent data suggest …

Invasion of bladder cancer (BC) cells from the mucosa into the muscle layer is canonical for
BC progression while phospholipase D isoform 1 (PLD1) is known to mediate development …

Urinary bladder cancer (UBC) is a common malignant tumor with high incidence. Advances
in the diagnosis and treatment of this disease demand the identification of novel therapeutic …

To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint
blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse …

Objective: To investigate perturbations in downstream signalling pathway activation and
potential resistance mechanisms to EGFR and/or HER2 inhibition in cell line models of …

Although combination chemotherapy is widely used for bladder cancer (BC) treatment, the
recurrence and progression rates remain high. Therefore, novel therapeutic targets are …

Continued smoking is highly associated with not only a higher incidence but also greater
risk of tumor recurrence, progression, and acquired chemoresistance of urothelial …

Transitional cell carcinoma (TCC) is the most common form of bladder cancer. In bladder
cancer, which in terms of its origins and genetics, is a representative of invasive tumors, the …